Among the synthetic growth hormone secretagogues, ipamorelin stands out for a single defining characteristic: selectivity. While older GHRPs like GHRP-2 and GHRP-6 produce significant GH release but also elevate cortisol, ACTH, and prolactin, ipamorelin stimulates robust GH release with minimal off-target hormonal activity. This selectivity profile has made it one of the most studied and referenced GH secretagogues in the research literature.
What Is Ipamorelin?
Ipamorelin is a synthetic pentapeptide (five amino acids: Aib-His-D-2-Nal-D-Phe-Lys-NH2) and a selective agonist of the growth hormone secretagogue receptor (GHSR-1a) — the ghrelin receptor. It was developed by Novo Nordisk and has been studied in multiple human Phase I and II clinical trials. Despite not reaching market approval, it generated a substantial body of research data that continues to inform GH secretagogue science.
Mechanism of Action
Ipamorelin mimics ghrelin at pituitary GHSR-1a receptors, triggering GH release through a mechanism distinct from GHRH. This creates an important pharmacological opportunity: combining ipamorelin with a GHRH analogue (like CJC-1295 or sermorelin) activates both primary GH release pathways simultaneously, producing synergistic GH output greater than either compound alone.
What makes ipamorelin unique among GHRPs:
- No meaningful cortisol elevation at research doses — unlike GHRP-2 and GHRP-6 which consistently elevate cortisol
- No significant ACTH stimulation — avoids the adrenal axis side effects of other GHRPs
- Minimal prolactin effect — prolactin elevation is a common side effect of older GHRPs
- No significant appetite stimulation — unlike GHRP-6 which notably increases hunger through ghrelin pathway activation
Research Findings
GH Release: Ipamorelin produces dose-dependent, robust GH release in both animal and human studies. At research doses, it generates GH pulses comparable in magnitude to GHRP-2 and GHRP-6 without their off-target hormonal effects.
Bone Density: In aged female rats, ipamorelin treatment significantly increased bone mineral content and density over 12 weeks — consistent with GH/IGF-1’s known role in bone remodeling. This was one of the primary indications explored in early clinical development.
Body Composition: Animal studies show ipamorelin treatment increases lean mass and reduces fat mass over time through GH/IGF-1 axis activation — effects consistent across multiple species studied.
GI Motility: An interesting and clinically relevant finding: ipamorelin (and ghrelin pathway agonists generally) accelerate gastric emptying and intestinal transit. Research has explored ipamorelin specifically for postoperative ileus — the gut motility dysfunction that commonly follows abdominal surgery. Phase II trials showed promising results in this indication.
Safety Profile: Human trials consistently show ipamorelin is well-tolerated, with adverse effects limited primarily to mild, transient flushing at higher doses — significantly cleaner than older GHRP compounds.
Ipamorelin vs. Other GH Secretagogues
| Compound | GH Release | Cortisol | Appetite | Prolactin |
|---|---|---|---|---|
| Ipamorelin | High | Minimal | Minimal | Minimal |
| GHRP-2 | Very High | Significant | Mild | Moderate |
| GHRP-6 | High | Significant | Strong | Moderate |
| Hexarelin | Highest | Significant | Mild | Significant |
| MK-677 | High (sustained) | Minimal | Mild | Minimal |
The Ipamorelin + CJC-1295 Stack
The combination of ipamorelin with CJC-1295 (particularly the without-DAC form for physiological pulsatility) is the most studied and discussed GH secretagogue stack in the research community. By activating both the GHSR pathway (ipamorelin) and the GHRH pathway (CJC-1295) simultaneously, researchers consistently observe synergistic GH release substantially greater than either compound alone — while maintaining ipamorelin’s clean selectivity profile.
Conclusion
Ipamorelin’s combination of potent GH release, exceptional selectivity, and clean safety profile makes it the benchmark GHRP for research applications. Whether studied alone or in combination with GHRH analogues, it provides one of the most well-characterized tools available for GH axis research. Combat Research carries research-grade ipamorelin independently verified for purity and identity.
For research purposes only. Not for human therapeutic use.
Related Research Articles
Shop Ipamorelin at Combat Research
Research-grade Ipamorelin at ≥99% purity. Available standalone or pre-blended with CJC-1295 for synergistic GH axis research.
